Publication | Open Access

Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

Rheumatoid DisorderRheumatologyAutoimmune DiseaseSjögren’s SyndromePhase 2BSystemic SclerodermaImmunologyClinical TrialsInflammatory Rheumatic DiseasePharmacotherapySclerodermaMedicinePrimary SjögrenRheumatoid ArthritisSubcutaneous Ianalumab